A $50 million October raise just pushed Aclaris's cash runway through the first half of 2029, funding Phase 2b trials of ATI-052 and modzatinib. Top-line ADMIRATION results for bosakitug in atopic dermatitis land this quarter, making the next few weeks the real catalyst.
Latest Activity
ACRS Coverage
Here Are Friday’s Top Wall Street Analyst Research Calls: Broadcom, Circle Internet, Kenvue, Medtronic, Sandisk, Southwest Airlines, Spotify, and More
Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a day can make. After a blockbuster rally on Wednesday, the stock market…
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More
Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.
BP, Conagra, Mattel, Pepsi, UnitedHealth and More Wednesday Afternoon Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including BP, Conagra Brands, Mattel, Norwegian Cruise Line, PepsiCo and UnitedHealth.
Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?
Aclaris shares more than doubled to start out the week after the company announced positive results from its mid-stage rheumatoid arthritis study.